LIFELINE BIOTECH (OTCMKTS:LLBO) started a project for developing and commercializing a technology that helped in early detection of breast cancer. However, a few years in, it decided that working on this project alone would be an expensive affair. That’s why in 2008, the company formed a private company, named as First Warnings Systems and gave it the license. As of now, the company is known as Cyrcadia Health.
The new private firm immediately started working on the project and by the looks of proceedings; it appears the company has made a considerable progress in the past few years. However, the things are bit different over at Lifeline’s camp. In 2010, it stopped filing its financial results and its profile at the OTC platform was given a dreaded Stop sign. As a result, LLBO shares plunged deep to the triple-zero levels. The volumes disappeared, and LLBO stocks were left dead in the water.
The turnout of events
LIFELINE BIOTECH (OTCMKTS:LLBO) filed some financial reports in November 2014, and it is after that the company’s stocks started getting some interest back. The company also released a couple of Press Releases that fetched investors’ attention. Things started slowly, but the ticker progressively picked up some pace. About a month ago, its share price surpassed the triple-zero range, and the credit goes to a press release that came last Thursday.
The press release
The press release of Lifeline Biotech stated that Cisco Systems, Inc. (NASDAQ:CSCO) has recorded a documentary named as Detected, which is expected to be premiered during the SxSW festival in Texas. It stated that the study of the iTBra is going to commence, and the device is expected to be on sale in early 2016. On Friday, LLBO shares made a 52-week high of 0.0045 and closed the day at $0.0043 with gains of more than 48%.